ga naar hoofdinhoud
Vademecum Hoofd-halstumoren Hoofd-hals plaveiselcelcarcinoom (PCC) Literatuur en richtlijnen
Voorlezen

Literatuur

  1. Driessen C. et al. Toxicity and efficacy of accelerated radiotherapy with concurrent weekly cisplatin for locally advanced head and neck carcinoma. Head & Neck. 2016; 38:1:E559-65
  2. Bonner J. et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006; 354(6):567-78
  3. Vermorken J. et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008; 359(11):1116-27
  4. Ferris R et al. Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. Oral Oncol. 2018; 81:45-51
  5. Burtness B et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. The Lancet. 2019; vol. 394, issue 10212, p1915-1928

Commissie BOM adviezen

Ga naar de commissie BOM adviezen over hoofd-halstumor.

Richtlijnen

Ga naar de richtlijn Hoofd-halstumoren in de FMS richtlijnen­database.